Actelion Passes On Trophos Acquisition After Failed Lou Gehrig's Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Actelion decides not to exercise its option to acquire the Marseille-based French biotech Trophos after the failure of that company's lead compound, olesoxime, in a Phase III study in amyotrophic lateral sclerosis